Abstract
Response adaptive designs are used in phase III clinical trial for skewing the allocation pattern towards the better treatments. We use optimum design theory to derive adaptive designs when the responses are normally distributed. The performance of the designs is studied with respect to the loss and the proportion of allocation to different treatments. The adaptive design does not affect inference.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
